STX-478: Clinical Trials

1 trial of STX-478, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow STX-478: new trials by email Literature Review of STX-478 trials Research Report on STX-478

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult
Phase 1 / Phase 2RecruitingEli Lilly and Company8802023-04-172026-07-07

Conditions studied

Breast Diseases (1)  ·  Breast Neoplasms (1)  ·  Endometrial Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Ovarian Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Eli Lilly and Company (1)

Countries

Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Spain (1)  ·  United States (1)

NIH funding

2023 (1)